Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Medical Product Outsourcing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Medical Product Outsourcing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

FDA Guidance on Off-Label Communication, Part 1

50:08
 
Share
 

Manage episode 485792824 series 2805302
Content provided by Medical Product Outsourcing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Medical Product Outsourcing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re speaking about off-label communication. More specifically, we’re reviewing a recent guidance from the FDA that offers insights on how off-label communication can be performed in accordance to the regulation. We get a definition of the topic as well as examples of successful off-label communication efforts. During the discussion, the following questions are addressed:

  • Can you first please provide an explanation of what “off-label” is in terms of the FDA?
  • Before getting into the details of this “new” guidance, what is the difference between Off-Label Use vs. Off-Label Communication?
  • What’s new in this “final” guidance?
  • What is meant by firm-initiated communication containing scientific information on unapproved uses?
  • If you communicate with an organization about unapproved (or off-label) uses, what will happen?
  • If you send such a communication, are you acknowledging the off-label use and then need to submit it to FDA for a label expansion?
  • Does FDA need to know about the communication?
  • What else is important?
  • What are the most important takeaways?

Listen to this discussion and see if you can benefit from off-label communication. Then check out part 2 of this discussion. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at [email protected], and we’ll see if we want to address your ideas/inquiries/suggestions in a future episode.

Send us a text

For more medtech news and information, visit https://www.mpomag.com.

  continue reading

151 episodes

Artwork
iconShare
 
Manage episode 485792824 series 2805302
Content provided by Medical Product Outsourcing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Medical Product Outsourcing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re speaking about off-label communication. More specifically, we’re reviewing a recent guidance from the FDA that offers insights on how off-label communication can be performed in accordance to the regulation. We get a definition of the topic as well as examples of successful off-label communication efforts. During the discussion, the following questions are addressed:

  • Can you first please provide an explanation of what “off-label” is in terms of the FDA?
  • Before getting into the details of this “new” guidance, what is the difference between Off-Label Use vs. Off-Label Communication?
  • What’s new in this “final” guidance?
  • What is meant by firm-initiated communication containing scientific information on unapproved uses?
  • If you communicate with an organization about unapproved (or off-label) uses, what will happen?
  • If you send such a communication, are you acknowledging the off-label use and then need to submit it to FDA for a label expansion?
  • Does FDA need to know about the communication?
  • What else is important?
  • What are the most important takeaways?

Listen to this discussion and see if you can benefit from off-label communication. Then check out part 2 of this discussion. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at [email protected], and we’ll see if we want to address your ideas/inquiries/suggestions in a future episode.

Send us a text

For more medtech news and information, visit https://www.mpomag.com.

  continue reading

151 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play